Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar|
|Abstract:||This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.|
|Inventor(s):||Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Salem, CT), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA), Smith; Christine (San Diego, CA), Lokensgard; David M. (San Diego, CA), Fineman; Mark (San Diego, CA), Ong; John (San Diego, CA)|
|Assignee:||Alkernnes Pharma Ireland Limited (Dublin, IE) Amylin Pharmaceuticals, Inc. (San Diego, CA)|
|Filing Date:||Apr 15, 2005|
|Claims:||1. A process of preparing a pharmaceutically acceptable composition in the form of microparticles for the sustained release of exendin-4 comprising: a) forming a mixture by combining an aqueous phase comprising water soluble exendin-4 polypeptide and sucrose in the absence of ammonium sulfate with an oil phase comprising a purified 50:50 DL PLG 4A polymer in methylene chloride, wherein the purified polymer has an inherent viscosity of between about 0.3 and 0.5 dL/g; b) forming a water-in-oil emulsion of the mixture from step a, wherein the inner emulsion droplet size is about 0.1 to 1.2 microns; c) adding a coacervation agent to the mixture to form embryonic microparticles, wherein the coacervation agent is silicone oil added in an amount sufficient to achieve a silicone oil to polymer solvent ratio of from about 1:1 to about 1.5:1, and wherein the silicone oil is added to the water-in-oil emulsion in from about 3 minutes to about 5 minutes and the coacervation mixture is held for less than or about 1 minute; d) transferring the embryonic microparticles to a quench solvent at a ratio of 16:1(v/v) quench solvent to methylene chloride to harden the embryonic microparticles to form hardened micro articles, wherein the quench solvent is a heptane/ethanol mixture and the transfer time is less than or about 3 minutes; e) collecting the hardened microparticles; and f) drying the hardened microparticles; wherein the exendin-4 is resent at from about 3% w/w to about 5% w/w of the total weight of the composition; the composition has a C.sub.max to C.sub.ave ratio of about 3 or less; and the total pore volume of the composition is about 0.1 mL/g or less. |
2. The process of claim 1, wherein in step b, the inner emulsion droplet size is about 0.2 to 0.4 microns.
3. The process of claim 1, wherein the exendin-4 is present at about 5% w/w of the total weight of the composition.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.